TIGIT deficiency promotes autoreactive CD4+ T-cell responses through a metabolic‒epigenetic mechanism in autoimmune myositis

  • Nat Commun. 2025 May 15;16(1):4502. doi: 10.1038/s41467-025-59786-z.
Yimei Lai  #  1 Shuang Wang  #  1 Tingting Ren  #  1 Jia Shi  1 Yichao Qian  1  2 Shuyi Wang  1  2 Mianjing Zhou  1 Ryu Watanabe  3 Mengyuan Li  1 Xinyuan Ruan  1 Xin Wang  4 Lili Zhuang  1 Zunfu Ke  2  5  6 Niansheng Yang  1 Yuefang Huang  4 Hui Zhang  7  8
Affiliations
  • 1. Department of Rheumatology and Clinical immunology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • 2. Institute of Precision Medicine, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • 3. Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • 4. Department of Pediatrics, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • 5. Department of Pathology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • 6. Molecular Diagnosis and Gene Test Centre, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • 7. Department of Rheumatology and Clinical immunology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. [email protected].
  • 8. Institute of Precision Medicine, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. [email protected].
  • # Contributed equally.
Abstract

Polymyositis (PM) is a systemic autoimmune disease characterized by muscular inflammatory infiltrates and degeneration. T-cell immunoreceptor with Ig and ITIM domains (TIGIT) contributes to immune tolerance by inhibiting T cell-mediated autoimmunity. Here, we show that a reduced expression of TIGIT in CD4+ T cells from patients with PM promotes these cells' differentiation into Th1 and Th17 cells, which could be rescued by TIGIT overexpression. Knockout of TIGIT enhances muscle inflammation in a mouse model of experimental autoimmune myositis. Mechanistically, we find that TIGIT deficiency enhances CD28-mediated PI3K/Akt/mTOR co-stimulatory pathway, which promotes glucose oxidation, citrate production, and increased cytosolic acetyl-CoA levels, ultimately inducing epigenetic reprogramming via histone acetylation. Importantly, pharmacological inhibition of histone acetylation suppresses the differentiation of Th1 and Th17 cells, alleviating muscle inflammation. Thus, our findings reveal a mechanism by which TIGIT directly affects the differentiation of Th1 and Th17 T cells through metabolic‒epigenetic reprogramming, with important implications for treating systemic autoimmune diseases.

Products